Studies in mice suggest that tweaking cholesterol levels with avasimibe, a lipid-lowering drug, may boost the effectiveness of new immunotherapy drugs, such as nivolumab (Opdivo) and pembrolizumab (Keytruda). Adding avasimibe to PD-1 inhibitors improved tumour inhibition and increased survival in mice.

Read more here.